Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7201 to 7215 of 7707 results

  1. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)

    This guidance has been updated and replaced by NICE technology appraisal guidance 684.

  2. Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management (CG102)

    This guideline has been updated and replaced by NICE guideline NG240.

  3. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    In development [GID-TA11264] Expected publication date: TBC

  4. BPMpathway for rehabilitation support in joint replacement surgery (MIB319)

    MIB319 BPMpathway for rehabilitation support in joint replacement surgery has been withdrawn. This is because factual inaccuracies have been identified. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, therefore these are no longer being reviewed.

  5. Spesolimab for preventing generalised pustular psoriasis flares [ID6216]

    In development [GID-TA11189] Expected publication date: TBC

  6. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    In development [GID-TA11476] Expected publication date: TBC

  7. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care (DG30)

    This guidance has been updated and replaced by NICE's diagnostics guidance 56.

  8. Medicines optimisation: key therapeutic topics – Integrated process statement (PMG13)

    February 2022: we have withdrawn our medicines optimisation: key therapeutic topics.

    We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy.

    If you have any queries, please contact nice@nice.org.uk.

  9. Developing NICE guidelines: how to get involved (PMG22)

    October 2018: This process guide has been updated. The updated version can be found in the tools and resources for developing NICE guidelines: the manual.

  10. Process manual for the endorsement of guidance and quality standard support resources (PMG29)

    The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.

  11. Key therapeutic topics – Medicines management options for local implementation: Interim process statement (PMG7)

    February 2022: we have withdrawn our medicines optimisation: key therapeutic topics.

    We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy.

    If you have any queries, please contact nice@nice.org.uk.